Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

98.70USD
17 Oct 2014
Price Change (% chg)

$1.92 (+1.98%)
Prev Close
$96.78
Open
$97.51
Day's High
$99.15
Day's Low
$97.31
Volume
4,383,753
Avg. Vol
2,064,665
52-wk High
$108.77
52-wk Low
$86.09

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products... (more)

Overall

Beta: 0.61
Market Cap (Mil.): $278,362.31
Shares Outstanding (Mil.): 2,820.29
Dividend: 0.70
Yield (%): 2.84

Financials

  JNJ.N Industry Sector
P/E (TTM): 16.36 32.64 33.19
EPS (TTM): 6.03 -- --
ROI: -- 18.40 17.65
ROE: -- 19.06 18.46
Search Stocks

J&J beats forecasts, helped by hepatitis drug

- Johnson & Johnson reported strong quarterly earnings on surging sales of a new treatment for hepatitis C, but the company said it had sharply reduced prices for its artificial hips and warned that profits could be hurt next year by the stronger dollar.

14 Oct 2014

UPDATE 3-J&J beats forecasts, helped by hepatitis drug

(Adds analyst comment, details on price cuts, stronger dollar; updates stock price)

14 Oct 2014

US STOCKS-Wall St to open higher after 3-day slump, earnings

* Futures up: Dow 59 pts, S&P 10.25 pts, Nasdaq 25.5 pts (Updates prices, adds premarket actives)

14 Oct 2014

US STOCKS-Futures higher after 3-day drop, earnings

* Futures up: Dow 93 pts, S&P 14.25 pts, Nasdaq 31.5 pts (Updates prices, adds premarket actives)

14 Oct 2014

US STOCKS-Futures little changed after 3-day drop; earnings due

NEW YORK, Oct 14 - U.S. stock index futures were little changed on Tuesday, after the S&P 500 suffered its worst three-day drop since November 2011, ahead of earnings results from companies such as Johnson & Johnson and Citigroup .

14 Oct 2014

Deals of the day- Mergers and acquisitions

(Adds Johnson & Johnson, Murphy Oil Corp, Bpifrance, UnitedHealth Group, Brookfield Asset Management, Third Point LLC, Nova KBM and Banca Carige)

30 Sep 2014

Johnson & Johnson to buy private drug developer for $1.75 billion

- Johnson & Johnson agreed to pay $1.75 billion in cash to buy privately held Alios BioPharma Inc, which is developing a drug for a common respiratory viral infection in children for which there is no approved treatment.

30 Sep 2014

UPDATE 2-Johnson & Johnson to buy private drug developer for $1.75 bln

Sept 30 - Johnson & Johnson agreed to pay $1.75 billion in cash to buy privately held Alios BioPharma Inc, which is developing a drug for a common respiratory viral infection in children for which there is no approved treatment.

30 Sep 2014

Johnson & Johnson to buy private drug developer for $1.75 bln

Sept 30 - Johnson & Johnson said it would buy privately held drug developer Alios BioPharma Inc for $1.75 billion in cash, to access a portfolio of drugs targeting viral infections.

30 Sep 2014

Coke, J&J join big companies behind new employee wellness push

WASHINGTON - Leaders of some of the biggest U.S. corporations, from Coca-Cola Co to Johnson & Johnson , unveiled a campaign on Tuesday to reduce the nation's healthcare costs, urging their peers to embrace wellness programs to improve employee health.

16 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks